Compare IDN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | IMUX |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.7M | 152.6M |
| IPO Year | 2014 | 2013 |
| Metric | IDN | IMUX |
|---|---|---|
| Price | $4.33 | $11.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.33 | ★ $36.00 |
| AVG Volume (30 Days) | 621.4K | ★ 845.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 38.00 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $140.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.67 | $0.51 |
| 52 Week High | $9.08 | $13.30 |
| Indicator | IDN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 24.47 | 72.08 |
| Support Level | N/A | $0.75 |
| Resistance Level | $5.34 | $13.30 |
| Average True Range (ATR) | 0.47 | 0.95 |
| MACD | -0.44 | -0.21 |
| Stochastic Oscillator | 7.22 | 56.74 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.